琼玉膏干预实验肺癌小鼠骨髓抑制的效应

背景骨髓抑制是应用抗肿瘤药物治疗的主要副反应.目的观察传统中药方琼玉膏对实验性肺癌小鼠化疗导致的骨髓抑制的干预效应.设计随机对照试验.单位暨南大学医学院.材料实验于2001-03/10在暨南大学医学院中心试验室完成.选用48只健康的6～8周龄C57/BL小鼠.方法使用癌细胞接种的方法制造小鼠肺癌模型,造模后随机均分3组,每组16只.①对照组,接种后次日用生理盐水0.2 mL灌胃,同时以5 μL/g体质量腹腔注射生理盐水,1次/d.②化疗组,顺氨氯铂20mg,用生理盐水稀释成0.2 g/L,以5 μL/g体质量腹腔注射,1次/d;同时以生理盐水0.2mL灌胃,1次/d.③联合组,除按化疗组用顺氨氯铂外,同时用琼玉膏0.2 mL灌胃,1次/d.于用药后21 d,检测外周血红细胞、白细胞、血小板数及骨髓有核细胞计数.主要观察指标各组小鼠外周血红细胞计数、白细胞计数、血小板计数及骨髓有核细胞计数.结果对照组有3只,化疗组有4只,联合组有4只未成瘤,被排除.在实验过程中对照组、化疗组各有2只死亡,联合组也有1只死亡,进入结果分析数对照组为11只、化疗组为10只、联合组为11只.①联合组及对照组的外周血红细胞、白细胞及血小板皆明显高于化疗组红细胞(8.54±0.81),(8.65±0.77),(4.56±1.00)]×1012 L-1;白细胞(9.04±0.60),(9.14±0.71),(3.31±0.96)]×109 L-1;血小板(949.09±111.31),(955.54±87.13),(399.30±131.36)]×109 L-1,P＜0.01].②化疗组骨髓有核细胞数明显低于联合组与对照组(5.30±1.12),(10.51±1.15),(14.36±1.02)]×106,P＜0.01).而联合组与对照组相比,对照组又高于联合组(P＜0.05).结论琼玉膏能提高肺癌小鼠化疗后外周血红细胞、白细胞、血小板及骨髓有核细胞计数,改善化疗所致的骨髓抑制状况,但尚不能完全拮抗化疗的骨髓抑制.

Qiongyugao for the bone marrow inhibition of mice with pulmonary adenocarcinoma

BACKGROUND: Bone marrow inhibition is a predominant side effect caused by the drugs for anti-tumor.OBJECTIVE: To observe the intervention effect of traditional Chinese medicine qiongyugao on bone marrow inhibition induced by chemotherapy in experimental mice with pulmonary adenocarcinoma.DESIGN: Randomized controlled trial.SETTING: Medical College of Jinan University.MATERIALS: The experiment was completed in the Central Laboratory of Medical College of Jinan University from March to October in 2001. Fortyeight healthy, aged 6 to 8 weeks C57/BL mice were involved.METHODS: The mouse model with pulmonary adenocareinoma was made with the method of inoculability of cancer cell, and then the models were group: On the following day of inoculation, 0.2 mL normal saline was used by gavage, and normal saline was injected intraperitoneally at the dosage of amine 20 mg was diluted into 0.2 g/L with normal saline, and performed intraperitoneal injection at the dosage of 5 μL/g, once per day, and 0.2 mL platinum diamine was used as in chemotherapy group and 0.2 mL qiongyugao was administered by gavage at the same time once per day. Peripheral erythrocyte, leukocyte and blood platelet, and karyota in bone marrow counting were detected on the 21 days after administration.MAIN OUTCOME MEASURES: Peripheral erythrocyte, leukocyte and blood platelet, and karyota in bone marrow counting of the mice in each group.RESULTS: Eleven mice failing to have tumor in tumor assessment were excluded from the sample, including 3 in the control group, 4 in the chemotherapy and 4 in the combination group. During the experiment,there were 2 mice dying in each group of the control group and chemotherapy group. Totally 11 mice in the control group, 10 in the chemotherapy group and 11 in the combination group entered the result analysis. Erythrocyte, leukocyte and blood platelets in the combination group and control group were all significantly higher than those in the chemotherapy group erythrocyte: (8.54 ±0.81 ), (8.65 ±0.77), (4.56 ±1.00) ×1012 L -1;leukocyte:(9.04 ±0.60), (9.14 ±0.71), (3.31 ±0.96) ×109 L -1;blood platelets:(949.09±111.31 ), (955.54±87.13), (399.30±131.36)× 109 L-1 ,P ＜ 0.01]. The number of karyota in bone marrow in the chemotherapy group was significantly lower than those in the combination group and control group (5.30±1.12),(10.51±1.15),(14.36±1.02)]×106,P ＜ 0.01); while the number of karyota in the control group was higher than that in the combination group (P ＜ 0.05).CONCLUSION: Qiongyugao can enhance the counting of erythrocyte,leucocyte, blood platelets of peripheral blood and karyota in bone marrow after chemotherapy in mice with pulmonary carcinoma, improve the inhibition of bone marrow induced by chemotherapy, but can not reverse it completely.